title: Anti-diabetic effect of blockade of the renin-angiotensin system.
abstract: Diabetes, which is frequently associated with hypertension, accelerates the development of hypertension-induced cardiovascular disease. Thus, the prevention of diabetes is important in the management of hypertension. Recent clinical megastudies have suggested that the blockade of the renin-angiotensin system (RAS) by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) inhibits new onset of diabetes. Thus, the agents to inhibit the RAS should be beneficial for glucose metabolism. However, the cardiovascular protective effects of ACE inhibitors and ARBs are not always superior to other classes of drugs. Further long-term clinical trials are necessary to clarify the anti-diabetic effect of the RAS-inhibiting agents.
authors.affiliation: Department of Nephrology and Endocrinology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Ando
authors.forename: Toshiro
authors.initials: T
authors.lastname: Fujita
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000187:drug effects*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents